10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
10x Genomics filed a Current Report on Form 8-K regarding its annual meeting of stockholders held on June 15, 2022, by live webcast. The report was signed and dated June 17, 2022. Holders representing approximately 82.13% of eligible voting power were present in person or by proxy, establishing a quorum.
Financial and Operating Metrics
This filing reports stockholder voting results and does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes Versus the Prior Comparable Period
The filing does not report a financial or operational comparison with a prior period or any material change in the company’s business, financial condition, or results of operations.
Annual Meeting Results
| Proposal | Outcome | Key Voting Results |
|---|---|---|
| Election of Class III directors | Approved | Sri Kosaraju, Mathai Mammen, M.D., Ph.D., and Shehnaaz Suliman, M.D., M. Phil., M.B.A. were elected to three-year terms expiring at the 2025 annual meeting, subject to earlier resignation or removal. |
| Ratification of Ernst & Young LLP | Approved | 236,807,826 votes for, 23,162 against, and 34,533 abstentions; no broker non-votes. |
| Advisory approval of executive compensation | Approved on a non-binding basis | 218,457,617 votes for, 6,555,421 against, 65,758 abstentions, and 11,786,725 broker non-votes. |
Guidance, Outlook, Risks, and Unusual Items
The filing provides no management guidance, outlook, financial contingencies, or risk updates. The principal reported matters are the director elections, auditor ratification, and advisory executive-compensation vote.
Important Facts to Verify
- Confirm the elected directors’ service terms and any subsequent changes to board composition.
- Verify Ernst & Young LLP’s appointment for the fiscal year ending December 31, 2022.
- Review the definitive proxy statement filed April 29, 2022 for details of executive compensation and the proposals.
- Use the company’s periodic financial filings for revenue, profitability, cash flow, liquidity, debt, and outlook information not included in this Form 8-K.